← Back
Merck
MRK · listed on the New York Stock Exchange · worth $365.67 billion
$140.93
+3.83% today
No insider bought Merck stock in the last year. They sold it 26 times, $52.95 million in all. Five members of Congress reported trading Merck in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
2.5B shares
100% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, ten insiders sold Merck stock and none bought. None of the 26 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Jennifer Zachary, EVP, General Counsel.
Planned sales
Form 144 notices filed for Merck in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Chirfi Guindo filed to sell 10,000 shares on 13 Aug; sold 10,000 by 13 AugNotice on SEC.gov
Richard R. DeLuca filed to sell 11,699 shares on 12 Aug; no sale reported yetNotice on SEC.gov
Executive Jennifer Zachary filed to sell 80,315 shares on 12 Aug; no sale reported yetNotice on SEC.gov
US Congress
Members of Congress who reported trading Merck in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Merck.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 10SoldRichard R. DeLucaAug 10 · Traded Aug 6 · EVP&Pres, Merck Animal Heallth300 @ $131.02$39.3K
Aug 10SoldRichard R. DeLucaAug 10 · Traded Aug 6 · EVP&Pres, Merck Animal Heallth4,945 @ $130.23$644K
Aug 10SoldRichard R. DeLucaAug 10 · Traded Aug 6 · EVP&Pres, Merck Animal Heallth805 @ $131.02$105.5K
Aug 7SoldDavid Michael WilliamsAug 7 · Traded Aug 5 · EVP,Chief Info&Digital Officer34,705 @ $128.77$4.47M
21 more with Pro →Analysts, earnings and news
Analysts' price target
$129.74 average
27 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 4 quarters above
Q1 '26−$1.28 a share+$0.19
Q4 '25$2.04 a share+$0.03
Q3 '25$2.58 a share+$0.23
Q2 '25$2.13 a share+$0.10